Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29269441 | 0.90 | GPR119 (0.47) | GPR119ALOX5APFEN1CHEK2CYP2C9 | |
| SCHEMBL31270437 | 0.88 | GPR119 (0.46) | GPR119SCN9AALOX5APFEN1CHEK2 | |
| SCHEMBL29269506 | 0.84 | GPR119 (0.52) | GPR119SCN9AALOX5APFEN1CHEK2 | |
| SCHEMBL31270241 | 0.84 | GPR119 (0.43) | GPR119SCN9AALOX5APFEN1CHEK2 | |
| SCHEMBL31269794 | 0.84 | GPR119 (0.51) | GPR119SCN9ACHEK2 | |
| SCHEMBL31270293 | 0.83 | HTR6 (0.47) | GPR119ALOX5APFEN1CHEK2CYP2C9 | |
| SCHEMBL29269458 | 0.81 | HTR6 (0.44) | GPR119SCN9A | |
| SCHEMBL29269459 | 0.81 | HTR6 (0.44) | GPR119SCN9A | |
| SCHEMBL13106506 | 0.81 | GPR119 (0.51) | GPR119ALOX5APFEN1CHEK2CYP2C9 | |
| SCHEMBL31270108 | 0.80 | CHEK2 (0.53) | GPR119SCN9AALOX5APFEN1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118251383-A | Macrocyclic compounds as proteasome beta subunit type 5 inhibitors | 利德探索中心有限公司 | 2024-06-25 | — | — | CN | disclosed |